Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34⁺ cell therapy to induce fetal hemoglobin for sickle cell disease.

ABSTRACT: Sickle cell disease (SCD) is a common, severe genetic blood disorder. Current pharmacotherapies are partially effective and allogeneic hematopoietic stem cell transplantation is associated with immune toxicities. Genome editing of patient hematopoietic stem cells (HSCs) to reactivate fetal hemoglobin (HbF) in erythroid progeny offers an alternative potentially curative approach to treat SCD. Although the FDA released guidelines for evaluating genome editing risks, it remains unclear how best to approach pre-clinical assessment of genome-edited cell products. Here, we describe rigorous pre-clinical development of a therapeutic γ-globin gene promoter editing strategy that supported an investigational new drug application cleared by the FDA. We compared γ-globin promoter and BCL11A enhancer t

SUBMITTER: Katta V 

PROVIDER: S-EPMC11489559 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature